PreveCeutical Medical Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRVCF research report →
Price Chart
About the company
Vancouver, Canada-based PreveCeutical Medical Inc. operates as a health sciences company, focusing on the creation of both preventative and curative treatments derived from organic and nature-identical substances. The company's innovative pipeline includes a cannabinoid Sol-Gel Delivery system designed for nose-to-brain administration, offering potential relief for ailments such as pain, inflammation, seizures, and various neurological disorders.
- CEO
- Stephen Van Deventer
- IPO
- 2017
- Employees
- 7
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on PRVCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.96M
- P/E
- -5.00
- PEG
- 0.07
- P/S
- 0.00
- P/B
- -1.44
- EV/EBITDA
- -10.07
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 23.09%
- ROIC
- 339.03%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-14,412-105.4%
- Op Income
- $-3,364,366
- Net Income
- $-1,583,019-34.8%
- EPS
- $-0.00-22.7%
- OCF Growth
- -302.7%
- FCF Growth
- -301.7%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.07
- RSI (14)
- 55
- Avg Volume
- 20.95K
No earnings-call transcripts are available for PRVCF yet.
- Free Float
- 67.3%
- Shares Outstanding
- 598.19M
- Float Shares
- 402.32M
Our PRVCF coverage
Recent articles, reports, and earnings notes.
No research on PRVCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRVCF report →PreveCeutical Closes Fourth Tranche of Non-Brokered Private Placement
newsfilecorp.com · Aug 4
PreveCeutical Closes Third Tranche of Non-Brokered Private Placement
newsfilecorp.com · Jul 27
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
newsfilecorp.com · Jun 12
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors
newsfilecorp.com · Jun 8
PreveCeutical Announces Extension of Non-Brokered Private Placement
newsfilecorp.com · May 19
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
newsfilecorp.com · May 12
PreveCeutical Announces Non-Brokered Private Placement
newsfilecorp.com · Apr 22
PreveCeutical Adopts Semi-Annual Financial Reporting
newsfilecorp.com · Apr 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.